VX-445/VX-661/VX-770 fixed-dose combination tablet
Sponsors
Vertex Pharmaceuticals Inc.
Conditions
Cystic Fibrosis
Phase 3
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105)
RecruitingCTIS2024-513754-29-00
Start: 2023-03-06Target: 15Updated: 2025-12-17
A Phase 3 Open-label Study Evaluating the Longterm Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects With Non-F508del CFTR Genotypes
Active, not recruitingCTIS2024-515637-14-00
Start: 2022-11-08Target: 295Updated: 2025-11-14